Point72 Asset Management L.P. Has $7.16 Million Stock Position in Alto Neuroscience, Inc. (NYSE:ANRO)

Point72 Asset Management L.P. increased its position in shares of Alto Neuroscience, Inc. (NYSE:ANRO) by 73.1% in the fourth quarter, HoldingsChannel reports. The firm owned 1,692,153 shares of the company’s stock after purchasing an additional 714,461 shares during the period. Point72 Asset Management L.P. owned approximately 0.06% of Alto Neuroscience worth $7,158,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its position in shares of Alto Neuroscience by 4.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 844,823 shares of the company’s stock worth $3,575,000 after purchasing an additional 36,319 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Alto Neuroscience during the 4th quarter worth about $3,542,000. Northern Trust Corp increased its position in shares of Alto Neuroscience by 198.1% during the 4th quarter. Northern Trust Corp now owns 587,135 shares of the company’s stock worth $2,484,000 after purchasing an additional 390,190 shares in the last quarter. Cantor Fitzgerald L. P. acquired a new stake in Alto Neuroscience in the 4th quarter valued at about $1,575,000. Finally, Integral Health Asset Management LLC acquired a new stake in Alto Neuroscience in the 4th quarter valued at about $1,269,000.

Alto Neuroscience Stock Up 1.2%

Shares of NYSE:ANRO opened at $2.56 on Tuesday. Alto Neuroscience, Inc. has a one year low of $1.60 and a one year high of $17.55. The company has a 50 day moving average of $2.36 and a 200-day moving average of $3.42. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09. The stock has a market cap of $69.30 million, a price-to-earnings ratio of -1.09 and a beta of 1.87.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.06. On average, sell-side analysts forecast that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current year.

Analyst Ratings Changes

ANRO has been the subject of several research reports. HC Wainwright initiated coverage on shares of Alto Neuroscience in a research report on Monday, April 7th. They issued a “buy” rating and a $10.00 price objective for the company. Wedbush restated a “neutral” rating and issued a $4.00 price objective on shares of Alto Neuroscience in a research report on Thursday, May 15th. Finally, William Blair restated an “outperform” rating on shares of Alto Neuroscience in a research report on Friday, March 21st. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $15.40.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.